Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Study: Triple-Hormone-Receptor Agonist Retatrutide for Obesity Journal: New England Journal of Medicine (NEJM) ClinicalTrials ID: NCT04881760 View Full Study Retatrutide is a glucagon, GLP-1, and GIP (triple hormone) receptor agonist being investigated to treat obesity
Nature 528(7581):262266
The best weight loss injection depends on individual tolerance, effectiveness, and side effect profile
It also can help speed up the metabolism, promoting weight loss
Full-text analysis was performed by the same two independent investigators
For patients using Ozempic, diabetic retinopathy complications may occur, particularly in those with pre-existing retinopathy
US$ 22.91
US$ 25.67
US$ 25.77
